HSG, formerly known as Sequoia Capital China, is a prominent venture capital and private equity firm with a global focus on technology, healthcare, and consumer sectors. Established in 2005, HSG operates offices in key international cities including Hong Kong, Shanghai, Beijing, Shenzhen, London, Tokyo, and Singapore, managing over $55 billion in assets for leading institutional investors. The firm has supported over 1,500 companies, fostering innovation and entrepreneurship through investments in transformative technologies and high-growth business models. HSG has a track record of success, with more than 160 portfolio companies having gone public and over 140 achieving unicorn status. It has developed a comprehensive investment platform that encompasses seed, venture, growth, buyout, and infrastructure investing, as well as public equities. HSG is dedicated to empowering entrepreneurs and companies to create enduring enterprises while delivering strong returns to its limited partners. Through its extensive resources and industry expertise, HSG provides significant advantages to the companies it partners with.
2800 Sand Hill Road, Suite 101 Menlo Park, California 94025, USA
Room 3606 China Central Place Tower 3 77 Jianguo Road Chaoyang District Beijing 100025, China
6th Floor, East Wing, Block B, Divyasree Technopolis, Off HAL Airport Road, Yemalur, Kadubeesanahalli, Bengaluru, Karnataka 560037, India
Wang Chenyu
Vice President
Sakshi Chopra
Managing Director
Amit Jain
Managing Director
Cherry Lu
Partner
Ishaan Mittal
Managing Director
Enita Pu
Partner
Harshjit Sethi
Managing Director
Tejeshwi Sharma
Managing Director
Pavel Vyhnalek
Operating Partner
Fu Xin
Partner
Past deals in Genetics
Generation Lab
Pre Seed Round in 2024
Generation Lab is focused on enhancing human health through the development of biological age testing services. The company aims to create a test that accurately assesses an individual's biological age and associated disease risks, utilizing clinically applicable biological evidence. By providing clinical-grade longevity reports and health span data analysis, Generation Lab enables healthcare professionals to optimize specific health areas based on the latest genomic research. The goal is to empower individuals to live longer and healthier lives by gaining insights into their biological age progression.
Neurophth Therapeutics
Series C in 2023
Neurophth is China's first gene therapy company for ophthalmic diseases. As a clinical-stage company, Neurophth is dedicated to discovering and developing gene therapies for patients suffering from blindness and other eye diseases globally.
Lingyi Biology
Series A in 2023
Lingyi Biology is a gene therapy company that uses a platform to validate the functionality of animal models of rare diseases. It is dedicated to sourcing innovation, with a focus on genetic rare diseases like metabolism, CNS, and ophthalmology. Lingyi Biology has a gene therapy and rare disease discovery, development, and industrialization team, as well as a rare disease animal model preparation and verification platform, to address the pain point of a lack of effective animal models for rare disease research and development.
GenAssist Therapeutics
Series A in 2022
GenAssist Therapeutics develops gene therapy drugs using base editing technology, which is advantageous in the field of DMD treatment. Founded in 2020, GenAssist was founded by outstanding scientists and industry experts in July 2020. They are committed to the development of gene editing drugs for a variety of genetic diseases.
Frontera Therapeutics
Series B in 2022
Frontera Therapeutics is a company specializing in adeno-associated virus (AAV) gene therapy, focused on developing and commercializing cost-effective recombinant virus-based therapies. The company aims to create a scalable platform that produces high-quality, affordable rAAV therapies for a range of genetic disorders, including ophthalmic, liver, metabolic, and neuromuscular diseases. Frontera Therapeutics has a diverse product pipeline that encompasses multiple therapeutic areas, with various candidates at different stages of development. By prioritizing affordability and quality, the company seeks to enhance the lives of patients through innovative genetic therapies.
NuProbe
Series B in 2022
NuProbe, Inc. is a genomics and molecular diagnostics company that focuses on noninvasive nucleic acid profiling and diagnostics. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in Shanghai, China, NuProbe has developed a platform that utilizes genetic toehold probes for quantitative PCR mutation detection. The company's innovative technology offers a Sample-In Answer-Out (SIAO) solution, which seamlessly integrates cell-free DNA extraction, qPCR analysis, sequencing, and bioinformatic interpretation. This precision diagnostic technology is designed to facilitate the early detection of cancer and infectious diseases by accurately capturing disease signatures with high sensitivity and multiplexing capability, allowing healthcare professionals to initiate timely interventions for patients.
Yueer Gene
Series B in 2022
Yueer is a genomics company driven by technology, with a number of revolutionary molecular detection technologies that can reduce the sequencing cost of all NGS platforms and the sensitivity of qPCR, Sanger, and nanopore sequencing. Yueer Gene collaborates with many partners to develop affordable, timely, and accurate genetic analysis tools in order to achieve precision medicine and improve patient outcomes.
Grit Science
Series A in 2022
Grit Science is a biotechnology company specializing in gene therapeutics, particularly focusing on the research and development of liver-related genes. The firm is dedicated to creating medical products and genetic treatments that address clinical needs and enhance human health. Through its innovative approach to biopharmaceutical technology, Grit Science aims to contribute significantly to the field of medicine by developing solutions that improve patient outcomes.
Lingyi Biology
Seed Round in 2022
Lingyi Biology is a gene therapy company that uses a platform to validate the functionality of animal models of rare diseases. It is dedicated to sourcing innovation, with a focus on genetic rare diseases like metabolism, CNS, and ophthalmology. Lingyi Biology has a gene therapy and rare disease discovery, development, and industrialization team, as well as a rare disease animal model preparation and verification platform, to address the pain point of a lack of effective animal models for rare disease research and development.
Neurophth Therapeutics
Series C in 2021
Neurophth is China's first gene therapy company for ophthalmic diseases. As a clinical-stage company, Neurophth is dedicated to discovering and developing gene therapies for patients suffering from blindness and other eye diseases globally.
Positive Sequence Biology
Series A in 2021
Positive Sequence Biology is a biotech company with new gene system-based editing, focused on biotech innovation & breakthrough therapies.
Geneus
Series B in 2021
Geneus develops and commercializes gene sequencers and reagents. The core of its technology is based on the characteristic current signal generated by the interaction of protein nanopores and nucleic acid bases, and it realizes single-molecule nucleic acid sequencing through an integrated chip system.
Biosysen
Seed Round in 2021
Biosysen is a synthetic biology company specializing in software-based species design and biomanufacturing. The company utilizes software engineering principles to enhance the self-replication and scalability of biological systems, aiming to unlock the full productivity potential of the biological industry. Biosysen's primary offerings include a library of artificial species and related industrial pipelines tailored for specific applications. These products cater to various sectors, including food production, medical testing, daily chemicals, and protein drug development, thereby supporting innovation and efficiency in these industries.
Analytical Biosciences
Series A in 2021
Analytical Biosciences is a single-cell genome developer that aims to create and apply accurate maps of human diseases. In collaboration with medical research institutions, hospitals, and pharmaceutical companies, we are committed to exploiting the application of single-cell genomics and bioinformatics in the diagnosis and treatment of human diseases. Through large-scale systematic disease single-cell mapping, big data intelligence mining is carried out to help a wide range of partners discover new therapeutic targets and develop new treatment strategies.
EdiGene
Series B in 2021
EdiGene Inc. is a biotechnology company based in Beijing, China, with additional offices in Guangzhou and Cambridge, Massachusetts. Founded in 2015, EdiGene specializes in the development of advanced genome editing technologies aimed at addressing various genetic diseases and cancer. The company focuses on both ex vivo and in vivo gene-editing therapies, utilizing proprietary platforms for modifying genetic information in human cells. Their innovative approaches include gene knockout, knock-in, and targeted mutations, which facilitate the creation of safer and more effective gene therapies. EdiGene also supports pharmaceutical research by providing high-throughput genome screening and drug target analysis, enhancing drug discovery efforts in the industry. Through its commitment to translating genome editing into therapeutics, EdiGene aims to improve human health outcomes and advance scientific research.
Benchling
Series E in 2021
Benchling, Inc. is a developer of a cloud-based informatics platform tailored for life sciences research and development. The platform includes a suite of integrated applications that allow scientists to design, share, and document experiments, as well as manage biological entities like plasmids and antibodies. Key features include Benchling Insights, which enables users to visualize and collaborate on structured data, and a biological registration system for inventory tracking. Benchling's solutions cater to a diverse range of applications such as gene therapy, vaccines, and industrial biotechnology, serving scientists in biotech, pharmaceutical, academic, and government sectors. Established in 2012 and based in San Francisco, the company aims to enhance the speed and collaboration of life science research by providing tools that streamline workflows and facilitate critical R&D decisions.
PackGene Biotech
Series C in 2021
PackGene Biotech, LLC is a biotechnology company based in the United States that specializes in developing viral vectors for gene therapies. It primarily focuses on adeno-associated virus (AAV) vectors, offering comprehensive services that include vector design, cloning, and packaging. The company also provides solutions for mRNA, plasmid DNA, and lentiviral vectors. With an emphasis on early-stage drug discovery and preclinical development, PackGene Biotech supports researchers in the medical industry by delivering high-purity, high-titer, and high-infectivity vectors for clinical applications. Its capabilities enable scalable and cost-effective production, facilitating advancements in cell and gene therapy trials.
Qihan Biotech
Series A in 2021
Qihan Biotech is a biomedical company based on genetic technology. Kaixin Bio ’s mission is to create a new world where patients do n’t have to wait for organ transplants. We are committed to using the world's advanced gene editing technology to produce safe and effective cells, tissues and organs that can be used for human transplantation, and to solve the serious shortage of organ transplant donors in China and the world.
Neurophth Therapeutics
Series B in 2021
Neurophth is China's first gene therapy company for ophthalmic diseases. As a clinical-stage company, Neurophth is dedicated to discovering and developing gene therapies for patients suffering from blindness and other eye diseases globally.
NuProbe
Series B in 2021
NuProbe, Inc. is a genomics and molecular diagnostics company that focuses on noninvasive nucleic acid profiling and diagnostics. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in Shanghai, China, NuProbe has developed a platform that utilizes genetic toehold probes for quantitative PCR mutation detection. The company's innovative technology offers a Sample-In Answer-Out (SIAO) solution, which seamlessly integrates cell-free DNA extraction, qPCR analysis, sequencing, and bioinformatic interpretation. This precision diagnostic technology is designed to facilitate the early detection of cancer and infectious diseases by accurately capturing disease signatures with high sensitivity and multiplexing capability, allowing healthcare professionals to initiate timely interventions for patients.
EdiGene
Series B in 2020
EdiGene Inc. is a biotechnology company based in Beijing, China, with additional offices in Guangzhou and Cambridge, Massachusetts. Founded in 2015, EdiGene specializes in the development of advanced genome editing technologies aimed at addressing various genetic diseases and cancer. The company focuses on both ex vivo and in vivo gene-editing therapies, utilizing proprietary platforms for modifying genetic information in human cells. Their innovative approaches include gene knockout, knock-in, and targeted mutations, which facilitate the creation of safer and more effective gene therapies. EdiGene also supports pharmaceutical research by providing high-throughput genome screening and drug target analysis, enhancing drug discovery efforts in the industry. Through its commitment to translating genome editing into therapeutics, EdiGene aims to improve human health outcomes and advance scientific research.
Neurophth Therapeutics
Series A in 2020
Neurophth is China's first gene therapy company for ophthalmic diseases. As a clinical-stage company, Neurophth is dedicated to discovering and developing gene therapies for patients suffering from blindness and other eye diseases globally.
BGI
Post in 2020
BGI is a biotechnology company specializing in genomics, providing genome sequencing and genetic testing services to research institutions and healthcare professionals. Operating through its subsidiary, Shenzhen Huada Gene Technology Co. Ltd., BGI offers a wide range of services including bioinformatics testing, agricultural genomics research, and proteomics research. The company collaborates with various organizations to enhance research efforts in the pharmaceutical and healthcare sectors. BGI also supplies products such as DNA extraction kits and other related tools, positioning itself as a key player in advancing genetic and genomic research.
ViGeneron
Series A in 2019
ViGeneron is dedicated to developing innovative gene therapies to treat ophthalmic diseases with high unmet medical need, as well as partnering with leading biopharmaceutical players in other disease areas. The company’s pipeline is built on two proprietary adeno-associated virus (AAV) technology platforms. The first, vgAAV gene therapy vector platform, allows superior transduction efficiency and intravitreal, less invasive treatment administration. The second, REVeRT vector platform, targets diseases caused by mutations in large genes. Privately-owned ViGeneron was founded in 2017 by a seasoned team with in-depth experience in AAV vector technology and clinical ophthalmic gene therapy programs and is located in Munich, Germany.
Qihan Biotech
Series A in 2019
Qihan Biotech is a biomedical company based on genetic technology. Kaixin Bio ’s mission is to create a new world where patients do n’t have to wait for organ transplants. We are committed to using the world's advanced gene editing technology to produce safe and effective cells, tissues and organs that can be used for human transplantation, and to solve the serious shortage of organ transplant donors in China and the world.
Burning Rock
Series C in 2019
Burning Rock is a cancer diagnostics company that specializes in individualized cancer treatment guidance. Established in March 2014 and headquartered in Beijing, the company utilizes advanced technologies such as Next-Generation Sequencing (NGS) and biomedical informatics to provide tailored solutions for cancer patients. Burning Rock operates a central laboratory in Guangzhou, along with a research and development center in Shanghai, collectively spanning over 10,000 square meters. The company offers a range of services, including tumor molecular pathology detection and cancer therapy selection, addressing the needs of both large hospitals through an in-hospital model and smaller hospitals via a central laboratory model. Its diverse product portfolio includes offerings like Pan-HEME and OncoScreen-WES, primarily generating revenue from its central laboratory business while also engaging in pharmaceutical research and development services.
BrightGene
Venture Round in 2019
BrightGene Bio-medical technology Co.,Ltd., is a leading Chinese biopharmaceutical company in small molecules and nucleotide drugs areas. Advised by China-based venture capital fund Laurel Venture Capital, BrightGene invests in all stage therapeutics and innovations.
Geneception
Series A in 2019
Geneception is a company focused on the development of breakthrough in gene and cell therapies that are fully-integrated.
Refuge Biotechnologies
Series B in 2018
Refuge Biotechnologies, Inc. is a Menlo Park, California-based company focused on developing cancer immunotherapies through the application of synthetic biology and gene-editing technology, specifically CRISPR-dCas. Founded in 2015, Refuge aims to enhance cell therapies by creating innovative treatments that can sense their environment and modulate multiple genes simultaneously. This approach allows for more potent and targeted cancer therapies, moving beyond traditional single-target treatments. The company's research and development efforts are centered on advancing both cancer diagnostics and immunotherapies to improve patient outcomes in cancer care.
NuProbe
Series A in 2018
NuProbe, Inc. is a genomics and molecular diagnostics company that focuses on noninvasive nucleic acid profiling and diagnostics. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in Shanghai, China, NuProbe has developed a platform that utilizes genetic toehold probes for quantitative PCR mutation detection. The company's innovative technology offers a Sample-In Answer-Out (SIAO) solution, which seamlessly integrates cell-free DNA extraction, qPCR analysis, sequencing, and bioinformatic interpretation. This precision diagnostic technology is designed to facilitate the early detection of cancer and infectious diseases by accurately capturing disease signatures with high sensitivity and multiplexing capability, allowing healthcare professionals to initiate timely interventions for patients.
Moderna
Series G in 2018
Moderna, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in developing therapeutics and vaccines using messenger RNA technology. Founded in 2010, the company focuses on various therapeutic areas, including infectious diseases, oncology, rare genetic disorders, and cardiovascular diseases. As of September 2024, Moderna has 40 mRNA development candidates in clinical development, demonstrating its commitment to advancing medical science. The company's mRNA platform has gained significant recognition, particularly with the authorization of its COVID-19 vaccine in December 2020. Moderna has established strategic collaborations with notable organizations such as AstraZeneca, Merck & Co., and the Bill & Melinda Gates Foundation. Additionally, it collaborates with Lonza Ltd. and Catalent for the manufacturing of its COVID-19 vaccine. Through its innovative approach, Moderna aims to provide effective solutions for a range of health challenges.
MedGenome
Series C in 2017
MedGenome is a company focused on developing genomics-based diagnostics and research platforms to enhance global health. Its innovative platform leverages advanced genomics technologies, bioinformatics, and big data analytics to analyze the genetic diversity of large populations. This approach aims to uncover the genetic foundations of various health conditions, including cancer, metabolic disorders, eye diseases, and rare diseases. MedGenome provides high-quality genetic diagnostic tests across multiple disease categories, such as immuno-oncology, infectious diseases, and reproductive health. By offering these insights, the company supports patients, pharmaceutical firms, and research institutions in understanding diseases at their genetic and molecular levels, ultimately contributing to improved healthcare outcomes.
Burning Rock
Series B in 2016
Burning Rock is a cancer diagnostics company that specializes in individualized cancer treatment guidance. Established in March 2014 and headquartered in Beijing, the company utilizes advanced technologies such as Next-Generation Sequencing (NGS) and biomedical informatics to provide tailored solutions for cancer patients. Burning Rock operates a central laboratory in Guangzhou, along with a research and development center in Shanghai, collectively spanning over 10,000 square meters. The company offers a range of services, including tumor molecular pathology detection and cancer therapy selection, addressing the needs of both large hospitals through an in-hospital model and smaller hospitals via a central laboratory model. Its diverse product portfolio includes offerings like Pan-HEME and OncoScreen-WES, primarily generating revenue from its central laboratory business while also engaging in pharmaceutical research and development services.
Burning Rock
Series A in 2015
Burning Rock is a cancer diagnostics company that specializes in individualized cancer treatment guidance. Established in March 2014 and headquartered in Beijing, the company utilizes advanced technologies such as Next-Generation Sequencing (NGS) and biomedical informatics to provide tailored solutions for cancer patients. Burning Rock operates a central laboratory in Guangzhou, along with a research and development center in Shanghai, collectively spanning over 10,000 square meters. The company offers a range of services, including tumor molecular pathology detection and cancer therapy selection, addressing the needs of both large hospitals through an in-hospital model and smaller hospitals via a central laboratory model. Its diverse product portfolio includes offerings like Pan-HEME and OncoScreen-WES, primarily generating revenue from its central laboratory business while also engaging in pharmaceutical research and development services.
MedGenome
Series B in 2015
MedGenome is a company focused on developing genomics-based diagnostics and research platforms to enhance global health. Its innovative platform leverages advanced genomics technologies, bioinformatics, and big data analytics to analyze the genetic diversity of large populations. This approach aims to uncover the genetic foundations of various health conditions, including cancer, metabolic disorders, eye diseases, and rare diseases. MedGenome provides high-quality genetic diagnostic tests across multiple disease categories, such as immuno-oncology, infectious diseases, and reproductive health. By offering these insights, the company supports patients, pharmaceutical firms, and research institutions in understanding diseases at their genetic and molecular levels, ultimately contributing to improved healthcare outcomes.
BGI
Venture Round in 2012
BGI is a biotechnology company specializing in genomics, providing genome sequencing and genetic testing services to research institutions and healthcare professionals. Operating through its subsidiary, Shenzhen Huada Gene Technology Co. Ltd., BGI offers a wide range of services including bioinformatics testing, agricultural genomics research, and proteomics research. The company collaborates with various organizations to enhance research efforts in the pharmaceutical and healthcare sectors. BGI also supplies products such as DNA extraction kits and other related tools, positioning itself as a key player in advancing genetic and genomic research.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.